PainReform (NASDAQ:PRFX – Get Free Report)‘s stock had its “hold” rating reiterated by analysts at Maxim Group in a report issued on Thursday, Benzinga reports.
PainReform Stock Performance
Shares of PRFX stock opened at $0.64 on Thursday. The firm has a fifty day moving average of $0.59 and a 200-day moving average of $0.62. PainReform has a 52-week low of $0.53 and a 52-week high of $20.16. The stock has a market cap of $1.29 million, a price-to-earnings ratio of -0.02 and a beta of 0.54.
PainReform (NASDAQ:PRFX – Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.40) EPS for the quarter.
Institutional Trading of PainReform
PainReform Company Profile
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
Featured Stories
- Five stocks we like better than PainReform
- What is a Dividend King?
- Texas Roadhouse Stock Steering for New Highs This Year
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.